Results 111 to 120 of about 21,108 (240)
Andrology, EarlyView.ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul +3 more
wiley +1 more source
Effects of dapagliflozin in experimental sepsis model in rats
, 2018 BACKGROUND: The aim of this study was to evaluate the possible protective effects of dapagliflozin in an experimental sepsis model in rats. METHODS: Saline (1 mL/kg, p.o.) or dapagliflozin (10 mg/kg, p.o.) was administered to Sprague-Dawley rats for 5 ...
ÇAM, MUHAMMET EMİN +7 more
core +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
Andrology, EarlyView.ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes
Diabetic Medicine, EarlyView.Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLT2i) have proven cardiorenal benefits in type 2 diabetes and are promising as adjunct‐to‐insulin therapy in participants with type 1 diabetes (T1D). However, clinical use in T1D has been limited owing to a lack of regulatory approval and the augmented risk of diabetic ketoacidosis (DKA ...
Julia Fielden +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon +14 more
wiley +1 more source